Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Patient compliance is of vital importance for the outcome of any medical therapy.

Compliance is especially a problem in long-term treatment of non-life threatening diseases, such as growth retardation in children.

Who Took Part

According to the abstract, 67 children were involved.

The age groups tagged for this paper are young children, children and teenagers.

The function and handling of the PenMate(TM) were evaluated in a Dutch trial by 27 GH-treated children with intrauterine growth retardation, aged 4-16 years, and their parents.

A similar trial was conducted in England, in which the NordiPen(TM) and the NordiPenMate(TM) were evaluated by 25 GH-treated children and their parents.

How the Study Was Run

The researchers set it up as a randomized, crossover and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

Acceptability/convenience and pain perception were evaluated by questionnaire after each period.

What Was Measured

Patient compliance is of vital importance for the outcome of any medical therapy.

The evaluation of the PenMate(TM) was based on a questionnaire.

PubMed files the paper under topics including Human Growth Hormone, Pain, Patient Compliance, Self Administration, Solutions and Surveys and Questionnaires.

What This Means in Plain Language

The paper is a randomized, crossover and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 67 children.

The publication is from 1999 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.